Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | ESR1 | P03372 | 6/20 | 0.76 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.76 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.76 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.76 |
| ▸ | DRD1 | P21728 | 1/20 | 0.76 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.76 |
| ▸ | KDR | P35968 | 1/20 | 0.76 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 5/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.73 |
| ▸ | ATM | Q13315 | 2/20 | 0.73 |
| ▸ | PGR | P06401 | 2/20 | 0.73 |
| ▸ | AR | P10275 | 2/20 | 0.73 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.73 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.73 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.73 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.73 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Estramustine SCHEMBL2348477 | 1.00 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL8173336 | 1.00 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL14031683 | 1.00 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL4252 | 1.00 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL29349776 | 1.00 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL29374661 | 1.00 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL13753350 | 1.00 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL7200287 | 1.00 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL679202 | 0.99 | RECQL (0.98) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL7621246 | 0.99 | RECQL (0.98) | RECQLBLMESR1ADORA3INPPL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6838469-B2 | Pharmaceutical composition that exhibits reduced side-effects comprising O-(3-piperidino-2-hydroxy-1-propyl)nicotinic acid amidoxime and a pyrimidine derivative with known antitumor activity | N-GENE RESEARCH LABORATORIES INC. (US) | 2005-01-04 | — | — | US | disclosed |
| WO-2004045611-A1 | USE OF A THIAZOLIDINEDIONE FOR THE REDUCTION OF SIDE EFFECTS OF CHEMOTHERAPY | N-GENE RESEARCH LABORATORIES INC. (US) | 2004-06-03 | — | — | WO | disclosed |
| EP-0993304-B1 | PHARMACEUTICAL COMPOSITION HAVING ENHANCED ANTITUMOR ACTIVITY AND/OR REDUCED SIDE EFFECTS, CONTAINING AN ANTITUMOR AGENT AND AN HYDROXAMIC ACID DERIVATIVE | N GENE RES LAB INC (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20030050345-A1 | Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroximic acid derivative | N-GENE RESEARCH LABORATORIES, INC. | 2003-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050345-A1 | Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroximic acid derivative | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HDGF, CA7 | RECQL 3073/4885BLM 4035/4885ESR1 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.